Keith Michael Sullivan

Journal article Semin Arthritis Rheum · June 2025 Preclinical models of inherited and induced autoimmune diseases (AIDs) have shown that hematopoietic stem cell transplantation (HSCT) following high-dose immunosuppressive conditioning could reverse organ damage and alter the course of AIDs. The rationale ... Full text Link to item Cite

Food insecurity prior to hematopoietic stem cell transplant is associated with malnutrition and worse outcomes.

Journal article Bone Marrow Transplant · June 2025 Food insecurity (FI), defined as the lack of continuous access to adequate food, affects 17-55% of cancer patients. Effects may be exacerbated in hematopoietic stem cell transplant (HSCT) patients, who face nutritional challenges due to treatment side effe ... Full text Link to item Cite

Cutaneous dysbiosis characterizes the post-allogeneic hematopoietic stem cell transplantation period.

Journal article Blood Adv · May 13, 2025 Gut dysbiosis is linked to mortality and the development of graft-versus-host disease after hematopoietic stem cell transplantation (HSCT), but the impact of cutaneous dysbiosis remains unexplored. We performed a pilot observational study, obtained retroau ... Full text Link to item Cite

Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long-Term Outcomes in a Prospective, Single-Arm Trial.

Journal article Arthritis Rheumatol · May 2025 OBJECTIVE: Two randomized trials for patients with diffuse systemic sclerosis (SSc) demonstrated an overall survival (OS) and event-free survival (EFS) advantage of autologous hematopoietic stem cell transplantation (AHSCT) using CD34+ selected peripheral ... Full text Link to item Cite

Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease.

Journal article Blood Adv · March 11, 2025 Disease-modifying therapies are standard of care (SOC) for sickle cell disease (SCD), but hematopoietic cell transplantation (HCT) has curative potential. We compared outcomes prospectively through 2 years after biologic assignment to a donor or no donor ( ... Full text Open Access Link to item Cite

The Cure of Thalassemia and the Angst of a Junior Attending.

Journal article Transplant Cell Ther · March 2025 Full text Link to item Cite

A retrospective study on beta-blocker use and outcomes in hematopoietic stem cell transplant patients.

Journal article PeerJ · 2025 Recent studies have linked beta-blocker (BB) use in critical care settings with improved survival outcomes, potentially due to beta-adrenergic receptor (β-AR) blockade and associated anti-inflammatory effects. Given the immune system's role in the developm ... Full text Link to item Cite

Toward a Cure for Autoimmune Diseases.

Journal article Transplant Cell Ther · October 2024 Full text Link to item Cite

A Year of Monthly Reflections

Journal article Transplantation and Cellular Therapy · July 1, 2024 Full text Cite

Caring for Our Patients, Their Loved Ones and Each Other.

Journal article Transplant Cell Ther · July 2023 Full text Link to item Cite

Reflections: A New Monthly Feature in Transplantation and Cellular Therapy.

Journal article Transplant Cell Ther · July 2023 Full text Link to item Cite

Improving outcomes in scleroderma: recent progress of cell-based therapies.

Journal article Rheumatology (Oxford) · June 1, 2023 Scleroderma is a rare, potentially fatal, clinically heterogeneous, systemic autoimmune connective tissue disorder that is characterized by progressive fibrosis of the skin and visceral organs, vasculopathy and immune dysregulation. The more severe form of ... Full text Link to item Cite

Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation.

Journal article Ann Rheum Dis · May 2023 OBJECTIVES: Results from the SCOT (Scleroderma: Cyclophosphamide Or Transplantation) clinical trial demonstrated significant benefits of haematopoietic stem cell transplant (HSCT) versus cyclophosphamide (CTX) in patients with systemic sclerosis. The objec ... Full text Link to item Cite

Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trials.

Journal article Pain · April 1, 2023 Herpes zoster (HZ) and HZ-associated pain greatly affect patients' quality of life, particularly in older and immunocompromised adults, for whom comorbidities and polypharmacy are often reported. Three phase III, randomized, placebo-controlled clinical tri ... Full text Link to item Cite

Enrollment Lessons from a Biological Assignment Study of Marrow Transplantation versus Standard Care for Adolescents and Young Adults with Sickle Cell Disease: Considerations for Future Gene and Cellular Therapy Trials.

Journal article Transplant Cell Ther · April 2023 We previously conducted a single-arm feasibility study (STRIDE1) of myeloablative bone marrow transplantation (BMT) in adolescents and young adults with sickle cell disease (SCD). The trial identified donors before entry, enrolled well, and found no unexpe ... Full text Link to item Cite

Myeloablative autologous haematopoietic stem cell transplantation resets the B cell repertoire to a more naïve state in patients with systemic sclerosis.

Journal article Ann Rheum Dis · March 2023 OBJECTIVES: Myeloablative autologous haematopoietic stem cell transplant (HSCT) was recently demonstrated to provide significant benefit over cyclophosphamide (CYC) in the treatment of diffuse cutaneous systemic sclerosis (dcSSc) in the Scleroderma: Cyclop ... Full text Link to item Cite

Clinical and Molecular Findings After Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data.

Journal article Arthritis Care Res (Hoboken) · February 2023 OBJECTIVE: Among individuals with systemic sclerosis (SSc) randomized to cyclophosphamide (CYC) (n = 34) or hematopoietic stem cell transplantation (HSCT) (n = 33), we examined longitudinal trends of clinical, pulmonary function, and quality of life measur ... Full text Link to item Cite

Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions.

Journal article Vaccine · January 4, 2023 Compared with the general population, older adults with immune senescence and individuals who are immunocompromised (IC) due to disease or immunosuppressive therapy are at increased risk for herpes zoster (HZ) and its associated complications, which can be ... Full text Link to item Cite

Editorial: Stem cell transplantation in autoimmune diseases (AID).

Journal article Front Immunol · 2023 Full text Link to item Cite

Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy.

Journal article Rheumatology (Oxford) · October 6, 2022 OBJECTIVES: The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial compared hematopoietic stem cell transplant to CYC treatment in patients with early SSc with progressive skin and lung or kidney involvement. Here we describe lymphocyte phenotyp ... Full text Link to item Cite

Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.

Journal article Hum Vaccin Immunother · November 2, 2021 Immunocompromised individuals, particularly autologous hematopoietic stem cell transplant (auHSCT) recipients, are at high risk for herpes zoster (HZ). We provide an in-depth description of humoral and cell-mediated immune (CMI) responses by age (protocol- ... Full text Link to item Cite

Re-evaluating inclusion criteria for autologous hematopoietic stem cell transplantation in advanced systemic sclerosis: Three successful cases and review of the literature.

Journal article J Scleroderma Relat Disord · June 2021 Systemic sclerosis is a chronic autoimmune disease with a poor prognosis, particularly when a patient has rapidly progressive skin or pulmonary involvement. Autologous hematopoietic stem cell transplant is an emerging treatment for this condition, that has ... Full text Link to item Cite

Quantifying Skin Stiffness in Graft-Versus-Host Disease, Morphea, and Systemic Sclerosis Using Acoustic Radiation Force Impulse Imaging and Shear Wave Elastography.

Journal article J Invest Dermatol · April 2021 Full text Link to item Cite

Large-Scale Characterization of Systemic Sclerosis Serum Protein Profile: Comparison to Peripheral Blood Cell Transcriptome and Correlations With Skin/Lung Fibrosis.

Journal article Arthritis Rheumatol · April 2021 OBJECTIVE: To provide a large-scale assessment of serum protein dysregulation in diffuse cutaneous systemic sclerosis (dcSSc) and to investigate serum protein correlates of SSc fibrotic features. METHODS: We investigated serum protein profiles of 66 partic ... Full text Link to item Cite

Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation.

Journal article Bone Marrow Transplant · January 2021 Prophylactic donor lymphocyte infusions (DLI) are used to augment post-transplant immune recovery to reduce both infectious complications and disease recurrence. Preclinical studies implicate the naive T-cell subset as the primary driver of graft-versus-ho ... Full text Link to item Cite

Clinical and Neuroimaging Correlates of Post-Transplant Delirium.

Journal article Biol Blood Marrow Transplant · December 2020 Delirium is common among adults undergoing hematopoietic stem cell transplantation (HCT), although the clinical and neuroimaging correlates of post-HCT delirium have not been adequately delineated. We therefore examined the frequency of delirium and neuroi ... Full text Link to item Cite

Cross-trial comparisons in reviews: proceed with caution.

Journal article Nat Rev Rheumatol · December 2020 Full text Link to item Cite

Machine learning predicts stem cell transplant response in severe scleroderma.

Journal article Ann Rheum Dis · December 2020 OBJECTIVE: The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial demonstrated clinical benefit of haematopoietic stem cell transplant (HSCT) compared with cyclophosphamide (CYC). We mapped PBC (peripheral blood cell) samples from the SCOT clini ... Full text Link to item Cite

Pre-Transplant Marital Status and Hematopoietic Cell Transplantation Outcomes.

Journal article Curr Oncol · December 2020 BACKGROUND: Evidence about the impact of marital status before hematopoietic cell transplantation (hct) on outcomes after hct is conflicting. METHODS: We identified patients 40 years of age and older within the Center for International Blood and Marrow Tra ... Full text Link to item Cite

Pre-Transplant Marital Status and Hematopoietic Cell Transplantation Outcomes.

Journal article Curr Oncol · December 1, 2020 Background: Evidence about the impact of marital status before hematopoietic cell transplantation (hct) on outcomes after hct is conflicting. Methods: We identified patients 40 years of age and older within the Center for International Blood and Marrow Tra ... Full text Link to item Cite

Safety and efficacy of HSCT for systemic sclerosis across clinical trials.

Journal article Nat Rev Rheumatol · November 2020 Full text Link to item Cite

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.

Journal article Lancet Respir Med · October 2020 BACKGROUND: A phase 2 trial of tocilizumab showed preliminary evidence of efficacy in systemic sclerosis. We assessed skin fibrosis and systemic sclerosis-associated interstitial lung disease (SSc-ILD) in a phase 3 trial to investigate the safety and effic ... Full text Link to item Cite

Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality.

Journal article PLoS One · 2020 Allogeneic-HCT (allo-HCT), while potentially curative, can result in significant complications including graft versus host disease (GVHD). Prior studies suggest that metabolic syndrome may be one risk factor for GVHD. We hypothesized that hepatic steatosis ... Full text Link to item Cite

Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT).

Journal article Biol Blood Marrow Transplant · December 2019 Herpes zoster (HZ) can have a substantial impact on quality of life (QoL). The vaccine efficacy (VE) of a recombinant zoster vaccine (RZV) was 68.2% (95% confidence interval [CI], 55.6% to 77.5%) in a phase 3 study in adult autologous hematopoietic stem ce ... Full text Link to item Cite

Allogeneic HSCT for autoimmune disease: a shared decision.

Journal article Nat Rev Rheumatol · December 2019 Full text Link to item Cite

Application of stem cell transplantation in autoimmune diseases.

Journal article Curr Opin Hematol · November 2019 PURPOSE OF REVIEW: Autologous hematopoietic stem cell transplantation (HSCT) is a promising therapeutic modality for severe autoimmune diseases. In this review, we will outline the immunological mechanisms and the clinical evidence and experiences for ther ... Full text Link to item Cite

High-dose intravenous immunoglobulin as adjuvant treatment for grade IV acute cutaneous graft-versus-host disease.

Journal article Br J Dermatol · October 2019 Full text Link to item Cite

Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures.

Journal article Ann Rheum Dis · October 2019 OBJECTIVE: In the randomised scleroderma: Cyclophosphamide Or Transplantation (SCOT trial) (NCT00114530), myeloablation, followed by haematopoietic stem cell transplantation (HSCT), led to improved clinical outcomes compared with monthly cyclophosphamide ( ... Full text Link to item Cite

Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial.

Journal article JAMA · July 9, 2019 IMPORTANCE: Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantat ... Full text Link to item Cite

Interrater Reliability of Clinical Grading Measures for Cutaneous Chronic Graft-vs-Host Disease.

Journal article JAMA Dermatol · July 1, 2019 IMPORTANCE: Cutaneous chronic graft-vs-host disease (cGVHD) is common after allogeneic hematopoietic stem cell transplant and is often associated with poor patient outcomes. A reliable and practical method for assessing disease severity and response to the ... Full text Link to item Cite

Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation.

Journal article Biol Blood Marrow Transplant · May 2019 Multiple sclerosis (MS) is a chronic, disabling, immune-mediated, demyelinating and degenerative disease of the central nervous system. Approved disease-modifying therapies may be incompletely effective in some patients with highly active relapsing disease ... Full text Link to item Cite

Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study.

Journal article Am J Hematol · April 2019 We conducted a multicenter pilot investigation of the safety and feasibility of bone marrow transplantation (BMT) in adults with severe sickle cell disease (SCD) (NCT 01565616) using a reduced toxicity preparative regimen of busulfan (13.2 mg/kg), fludarab ... Full text Link to item Cite

How I treat refractory chronic graft-versus-host disease.

Journal article Blood · March 14, 2019 Approximately 35% to 50% of patients otherwise cured of hematologic malignancies after allogeneic hematopoietic stem cell transplantation will develop the pleomorphic autoimmune-like syndrome known as chronic graft-versus-host disease (cGVHD). Since in 200 ... Full text Link to item Cite

Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.

Journal article Ann Rheum Dis · January 2019 OBJECTIVE: To assess survival and identify predictors of survival in patients with systemic sclerosis-interstitial lung disease (SSc-ILD) who participated in the Scleroderma Lung Studies (SLS) I and II. METHODS: SLS I randomised 158 patients with SSc-ILD t ... Full text Link to item Cite

Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation.

Journal article Biol Blood Marrow Transplant · October 2018 Systemic sclerosis is a progressive inflammatory disease that is frequently fatal and has limited treatment options. High-dose chemotherapy with autologous hematopoietic cell transplantation (AHCT) has been evaluated as treatment for this disease in observ ... Full text Open Access Link to item Cite

Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis.

Journal article Biol Blood Marrow Transplant · September 2018 For patients with acute lymphoblastic leukemia (ALL), allogeneic hematopoietic cell transplantation (alloHCT) offers a potential cure. Life-threatening complications can arise from alloHCT that require the application of sophisticated health care delivery. ... Full text Link to item Cite

Use of the National Institutes of Health Consensus Guidelines Improves the Diagnostic Sensitivity of Gastrointestinal Graft-Versus-Host Disease.

Journal article Arch Pathol Lab Med · September 2018 CONTEXT: - Graft-versus-host disease of the gastrointestinal tract is a common complication of hematopoietic stem cell transplant associated with significant morbidity and mortality. Accurate diagnosis can be difficult and is a truly clinicopathologic ende ... Full text Link to item Cite

Shared Decision-Making in Hematopoietic Stem Cell Transplantation for Sickle Cell Disease.

Journal article Biol Blood Marrow Transplant · May 2018 Full text Link to item Cite

Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Adults.

Journal article Biol Blood Marrow Transplant · April 2018 Gastrointestinal (GI) complications including graft-versus-host disease (GVHD) are a major cause of morbidity and mortality in allogenic stem transplant recipients. Although several studies have previously looked into the acute GI complications, fewer smal ... Full text Link to item Cite

An mHealth Pain Coping Skills Training Intervention for Hematopoietic Stem Cell Transplantation Patients: Development and Pilot Randomized Controlled Trial.

Journal article JMIR Mhealth Uhealth · March 19, 2018 BACKGROUND: Pain is a challenge for patients following hematopoietic stem cell transplantation (HCT). OBJECTIVE: This study aimed to develop and test the feasibility, acceptability, and initial efficacy of a Web-based mobile pain coping skills training (mP ... Full text Link to item Cite

Autologous Stem-Cell Transplantation for Severe Scleroderma.

Journal article N Engl J Med · March 15, 2018 Full text Link to item Cite

Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.

Journal article N Engl J Med · January 4, 2018 BACKGROUND: Despite current therapies, diffuse cutaneous systemic sclerosis (scleroderma) often has a devastating outcome. We compared myeloablative CD34+ selected autologous hematopoietic stem-cell transplantation with immunosuppression by means of 12 mon ... Full text Link to item Cite

High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.

Journal article Bone Marrow Transplant · January 2018 Single-agent high-dose melphalan (HDM, 200 mg/m2) has been the most commonly used conditioning regimen prior to autologous stem cell transplant, since its introduction in 1992. We used a more aggressive alkylator-based conditioning regimen in an attempt to ... Full text Link to item Cite

Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma.

Journal article Hematol Oncol · December 2017 We retrospectively studied 340 fit patients with multiple myeloma (MM) who underwent autologous stem cell transplantation (ASCT). We hypothesized that progression-free survival (PFS) of older patients was non-inferior to that of younger patients after ASCT ... Full text Link to item Cite

Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases.

Journal article Haematologica · November 2017 Advances in allogeneic hematopoietic cell transplantation for sickle cell disease have improved outcomes, but there is limited analysis of healthcare utilization in this setting. We hypothesized that, compared to late transplantation, early transplantation ... Full text Link to item Cite

Manufacture of Autologous CD34+ Selected Grafts in the NIAID-Sponsored HALT-MS and SCOT Multicenter Clinical Trials for Autoimmune Diseases.

Journal article Biol Blood Marrow Transplant · September 2017 To ensure comparable grafts for autologous hematopoietic cell transplantation (HCT) in the National Institute of Allergy and Infectious Diseases-sponsored Investigational New Drug protocols for multiple sclerosis (HALT-MS) and systemic sclerosis (SCOT), a ... Full text Link to item Cite

An mHealth Pain Coping Skills Training Intervention for Hematopoietic Stem Cell Transplantation Patients: Development and Pilot Randomized Controlled Trial (Preprint)

Journal article · July 27, 2017 BACKGROUNDPain is a challenge for patients following hematopoietic stem cell transplantation (HCT). Full text Cite

Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization.

Journal article Biol Blood Marrow Transplant · July 2017 Delayed hematopoietic recovery contributes to increased infection risk following umbilical cord blood (UCB) transplantation. In a Phase 1 study, adult recipients of UCB stem cells cultured ex vivo for 3 weeks with nicotinamide (NiCord) had earlier median n ... Full text Link to item Cite

Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.

Journal article Biol Blood Marrow Transplant · February 2017 Comprehensive recommendations for maintenance therapy after autologous stem cell transplantation (ASCT) for patients with multiple myeloma (MM) have yet to be defined. Bortezomib has been utilized as maintenance therapy after ASCT, but data attesting to th ... Full text Link to item Cite

Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial.

Journal article Clin Infect Dis · October 15, 2016 BACKGROUND: Respiratory viral infections (RVIs) are frequent complications of hematopoietic stem cell transplant (HSCT). Surgical masks are a simple and inexpensive intervention that may reduce nosocomial spread. METHODS: In this prospective single-center ... Full text Link to item Cite

Review: Hematopoietic Stem Cell Transplantation for Scleroderma: Effective Immunomodulatory Therapy for Patients With Pulmonary Involvement.

Journal article Arthritis Rheumatol · October 2016 Full text Open Access Link to item Cite

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery.

Journal article J Hematol Oncol · August 17, 2016 BACKGROUND: The binding of CXCR4 with its ligand (stromal-derived factor-1) maintains hematopoietic stem/progenitor cells (HSPCs) in a quiescent state. We hypothesized that blocking CXCR4/SDF-1 interaction after hematopoietic stem cell transplantation (HSC ... Full text Open Access Link to item Cite

The Diagnostic Yield of Site and Symptom-Based Biopsies for Acute Gastrointestinal Graft-Versus-Host Disease: A 5-Year Retrospective Review.

Journal article Dig Dis Sci · March 2016 BACKGROUND: Graft-versus-host disease (GVHD) complicates half of hematopoietic stem cell transplants (HCT), and the gastrointestinal tract is commonly affected. Endoscopic biopsies have a key role in the diagnosis. The optimal procedure(s) to perform and s ... Full text Link to item Cite

Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease.

Journal article Biol Blood Marrow Transplant · February 2016 Although a number of published trials exist of HLA-identical sibling hematopoietic cell transplantation (HCT) for sickle cell disease (SCD) that span 2 decades, when and for whom this therapy should be pursued is a subject of debate. Assessments of the ris ... Full text Link to item Cite

Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma.

Journal article J Clin Apher · June 2015 High-dose cyclophosphamide (Cy) is frequently employed for peripheral blood mobilization of hematopoietic stem cells before high-dose chemotherapy with autologous stem cell transplantation (ASCT) in multiple myeloma (MM). The benefit of mobilization with C ... Full text Link to item Cite

A HYBRID IN-PERSON AND MHEALTH PAIN COPING SKILLS INTERVENTION FOR STEM CELL TRANSPLANT PATIENTS

Journal article ANNALS OF BEHAVIORAL MEDICINE · April 1, 2015 Link to item Cite

A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients.

Journal article Blood · November 6, 2014 Recombinant herpes zoster (HZ) vaccines may be an alternative to the live-attenuated HZ vaccine for immunocompromised individuals. This was a phase 1/2, randomized, observer-blind, placebo-controlled study in adults with multiple myeloma, non-Hodgkin lymph ... Full text Link to item Cite

Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment.

Journal article J Clin Invest · July 2014 BACKGROUND: Delayed hematopoietic recovery is a major drawback of umbilical cord blood (UCB) transplantation. Transplantation of ex vivo-expanded UCB shortens time to hematopoietic recovery, but long-term, robust engraftment by the expanded unit has yet to ... Full text Open Access Link to item Cite

Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies.

Journal article Biol Blood Marrow Transplant · February 2014 We present a comparative study on 124 patients with hematologic malignancies who had undergone reduced-intensity conditioning and then received a transplant from an HLA-matched related (MRD), an HLA-matched unrelated (MUD), or an HLA-haploidentical related ... Full text Link to item Cite

Stem cell transplantation in systemic sclerosis.

Journal article Curr Opin Rheumatol · November 2013 PURPOSE OF REVIEW: The purpose of this review is to discuss recent published clinical and mechanistic studies on stem cell transplantation for systemic sclerosis and their implications for clinical practice. RECENT FINDINGS: Retrospective analyses of indep ... Full text Link to item Cite

Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment.

Journal article Bone Marrow Transplant · July 2013 High fevers and/or rashes prior to neutrophil engraftment are frequently observed after umbilical cord blood (UCB) transplantation, and the condition is referred to as pre-engraftment syndrome (PES). Few studies have evaluated the risk factors for and trea ... Full text Open Access Link to item Cite

Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial.

Journal article J Rheumatol · April 2013 OBJECTIVE: To describe the prevalence and clinical correlates of endoscopic gastric antral vascular ectasia (GAVE; "watermelon stomach") in early diffuse systemic sclerosis (SSc). METHODS: Subjects with early, diffuse SSc and evidence of specific internal ... Full text Link to item Cite

Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation.

Journal article Biol Blood Marrow Transplant · November 2012 Immunologic reconstitution after allogeneic hematopoietic cell transplantation is a critical component of successful outcome. Umbilical cord blood (UCB) transplantation in adult recipients is associated with slow and often inadequate immune recovery. We ch ... Full text Link to item Cite

Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry.

Journal article Cancer Invest · November 2012 Full text Link to item Cite

Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research.

Journal article Biol Blood Marrow Transplant · October 2012 Hematopoietic cell transplantation (HCT) is an emerging therapy for patients with severe autoimmune diseases (AID). We report data on 368 patients with AID who underwent HCT in 64 North and South American transplantation centers reported to the Center for ... Full text Link to item Cite

Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration.

Journal article Bone Marrow Transplant · August 2012 Plerixafor, given on day 4 of G-CSF treatment is more effective than G-CSF alone in mobilizing hematopoietic progenitor cells. We tested a strategy of preemptive plerixafor use following assessment of the peak mobilization response to 5 days of G-CSF. Pati ... Full text Link to item Cite

Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors.

Journal article Bone Marrow Transplant · June 2012 The impact of activating KIR (aKIR) and inhibitory KIR (iKIR) on OS, relapse-related mortality (RRM) and acute GVHD (aGVHD) was prospectively studied in 84 adults with high-risk hematologic malignancies receiving reduced intensity conditioning (RIC) T-cell ... Full text Link to item Cite

Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation.

Journal article Bone Marrow Transplant · May 2012 Primary graft failure after allogeneic hematopoietic cell transplantation is a life-threatening complication. A shortened conditioning regimen may reduce the risk of infection and increase the chance of survival. Here, we report the outcome of 11 patients ... Full text Link to item Cite

Haemopoietic stem-cell transplantation for systemic sclerosis.

Journal article Lancet · January 21, 2012 Full text Link to item Cite

Haemopoietic stem-cell transplantation for systemic sclerosis - Authors' reply

Journal article Lancet · January 1, 2012 Full text Cite

Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma.

Journal article Bone Marrow Transplant · June 2011 Positron emission tomography (PET) in conjunction with computed tomography is a frequently used modality for staging patients with lymphoma. Utility of PET-computed tomography before or early following auto-SCT has not been as rigorously evaluated. We retr ... Full text Link to item Cite

Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning.

Journal article Biol Blood Marrow Transplant · June 2011 High treatment-related mortality (TRM) and high graft failure rate are serious concerns in HLA-mismatched umbilical cord blood (UCB) transplantation with myeloablative conditioning. We conducted a prospective trial of dual UCB transplantation using modifie ... Full text Link to item Cite

Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States.

Journal article Biol Blood Marrow Transplant · May 2011 Recipients of hematopoietic cell transplantation may be at risk for developing acute kidney injury (AKI), and this risk may be increased in patients who undergo transplantation for severe systemic sclerosis (SSc) due to underlying scleroderma renal disease ... Full text Link to item Cite

Renal shielding and dosimetry for patients with severe systemic sclerosis receiving immunoablation with total body irradiation in the scleroderma: cyclophosphamide or transplantation trial.

Journal article Int J Radiat Oncol Biol Phys · March 15, 2011 PURPOSE: To describe renal shielding techniques and dosimetry in delivering total body irradiation (TBI) to patients with severe systemic sclerosis (SSc) enrolled in a hematopoietic stem cell transplant protocol. METHODS AND MATERIALS: The Scleroderma: Cyc ... Full text Link to item Cite

Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors.

Journal article Cancer Invest · January 2011 INTRODUCTION: High relapse rates and infections remain primary causes of failure in nonmyeloablative transplantation. Interleukin-2 (IL-2) may stimulate the immune system and improve outcomes. The primary objective of this pilot study was to evaluate the f ... Full text Link to item Cite

Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation.

Journal article Biol Blood Marrow Transplant · August 2010 Infusing natural killer (NK) cells following transplantation may allow less infections and relapse with little risk of acute graft-versus-host disease (aGVHD). We delivered 51 total NK cell-enriched donor lymphocyte infusions (DLIs) to 30 patients followin ... Full text Link to item Cite

Stem-cell transplantation for sickle cell disease.

Journal article N Engl J Med · March 11, 2010 Link to item Cite

Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease.

Journal article Biol Blood Marrow Transplant · February 2010 We conducted a prospective, multicenter investigation of human-leukocyte antigen (HLA) identical sibling bone marrow transplantation (BMT) in children with severe sickle cell disease (SCD) between 1991 and 2000. To determine if children were protected from ... Full text Link to item Cite

"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.

Journal article Biol Blood Marrow Transplant · January 2010 The purpose of this study was to evaluate the efficacy and safety of short-course bortezomib, melphalan, prednisone (VMP) in previously untreated multiple myeloma as frontline therapy for transplant-ineligible patients and induction prior to autologous ste ... Full text Link to item Cite

Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States.

Journal article Biol Blood Marrow Transplant · January 2010 Considerable advances have been made in our understanding of the immunobiology of autoimmune disease and its treatment with hematopoietic cell transplantation (HCT). In autoimmune disorders, the reconstituted immune system following lymphoablation and auto ... Full text Link to item Cite

Therapy with mycophenolate mofetil for refractory acute and chronic GVHD.

Journal article Bone Marrow Transplant · December 2009 We evaluated the pharmacokinetics and efficacy of oral mycophenolate mofetil (MMF) for treatment of refractory GVHD. In a prospective study of acute GVHD, 9 of 19 patients (47%) had a response and 10 (53%) had no improvement. Survival at 6 and 12 months af ... Full text Link to item Cite

Improvements in digital vasculature observed using micro magnetic resonance angiography after high-dose immunosuppression for severe systemic sclerosis.

Journal article Bone Marrow Transplant · September 2009 Full text Link to item Cite

Carbon monoxide diffusion capacity: how low can you go for hematopoietic cell transplantation eligibility?

Journal article Biol Blood Marrow Transplant · April 2009 Current guidelines suggest that patients with a pretransplantation diffusion capacity of the lung for carbon monoxide (DLCO) < or = 60% are not ideal candidates for hematopoietic cell transplantation (HCT); however, recent studies suggest this criterion ma ... Full text Link to item Cite

Pharmacologic Prevention of Acute Graft-Versus-Host Disease

Journal article · March 5, 2009 Full text Cite

Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors.

Journal article Bone Marrow Transplant · February 2009 We report the outcome of early donor lymphocyte infusions (DLIs) after T-cell depleted non-myeloablative transplantation using stem cells from HLA-matched or mismatched donors. Sixty-nine patients with high-risk hematologic malignancies received DLI follow ... Full text Link to item Cite

Early Pre/Post Fluoro-Deoxyglucose Positive Emission Tomography (PET) Does Not Predict Outcome of Patients Undergoing Hematopoietic Stem Cell Transplantation in Hodgkins Disease and Non-Hodgkins Lymphoma

Journal article BLOOD · November 16, 2008 Link to item Cite

Bortezomib Plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma

Journal article BLOOD · November 16, 2008 Link to item Cite

Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients.

Journal article Biol Blood Marrow Transplant · May 2008 The efficacy of once-daily intravenous busulfan with fludarabine as a preparative regimen for partially matched umbilical cord blood transplantation has not been formally studied. We randomized 10 adult patients with myeloid malignancies to receive either ... Full text Link to item Cite

Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection.

Journal article Bone Marrow Transplant · January 2008 Following initial graft rejection, a second attempt at allogeneic immunotherapy is often contemplated, but data on the success is limited. We therefore report on 11 patients with hematologic malignancies, renal cell cancer or marrow failure who underwent a ... Full text Link to item Cite

Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics.

Journal article Biol Blood Marrow Transplant · December 2007 End-organ damage is common in patients with sickle cell disease (SCD) thereby limiting the use of allogeneic stem cell transplantation (SCT). We report the outcome of 2 adult SCD patients, 1 with end-stage renal disease (ESRD), who underwent fludarabine-ba ... Full text Link to item Cite

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study.

Journal article Blood · August 15, 2007 More effective therapeutic strategies are required for patients with poor-prognosis systemic sclerosis (SSc). A phase 2 single-arm study of high-dose immunosuppressive therapy (HDIT) and autologous CD34-selected hematopoietic cell transplantation (HCT) was ... Full text Link to item Cite

Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research.

Journal article Br J Haematol · June 2007 We report outcomes after myeloablative haematopoietic cell transplantation (HCT) from human leucocyte antigen (HLA)-matched sibling donors in 67 patients with sickle cell disease transplanted between 1989 and 2002. The most common indications for transplan ... Full text Link to item Cite

Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.

Journal article J Clin Oncol · February 20, 2007 PURPOSE: Allogeneic transplantation is typically limited to younger patients having a matched donor. To allow a donor to be found for nearly all patients, we have used a nonmyeloablative conditioning regimen in conjunction with stem cells from a related do ... Full text Link to item Cite

Effect of myeloablative bone marrow transplantation on growth in children with sickle cell anaemia: results of the multicenter study of haematopoietic cell transplantation for sickle cell anaemia.

Journal article Br J Haematol · February 2007 Although haematopoietic cell transplantation (HCT) is curative for sickle cell anaemia (SCA), concerns about its short- and long-term toxicities limit its application. A potential toxicity is an adverse effect on growth. To identify an HCT growth effect, s ... Full text Link to item Cite

Normal interleukin-7 (IL7) levels and normal IL7 response to CD4 T lymphopenia in patients with multiple sclerosis and systemic sclerosis.

Journal article Clin Immunol · October 2006 Full text Link to item Cite

Cyclophosphamide in scleroderma lung disease.

Journal article N Engl J Med · September 14, 2006 Link to item Cite

Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis.

Journal article Arthritis Rheum · June 2006 OBJECTIVE: To evaluate the safety and efficacy of allogeneic hematopoietic cell transplantation (HCT) after myeloablative conditioning in patients with severe systemic sclerosis (SSc). METHODS: Eligibility criteria for the study included SSc patients with ... Full text Link to item Cite

Chronic graft-versus-host disease.

Journal article Blood Rev · January 2006 Chronic graft versus host disease (GVHD) remains today one of the most vexing late complications of allogeneic stem cell transplantation. Occurring a minimum of 100 days following stem cell transplantation, approximately 50% of patients will experience som ... Full text Link to item Cite

Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005.

Journal article Biol Blood Marrow Transplant · November 2005 Full text Link to item Cite

Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases).

Journal article Clin Immunol · December 2004 To ascertain the consequences of severe leukopenia and the tempo of recovery, we studied the immunity of 56 adult patients treated for multiple sclerosis or systemic sclerosis with autologous CD34 cell transplantation using extremely lymphoablative conditi ... Full text Link to item Cite

High dose immunotherapy with stem cell rescue in severe systemic sclerosis: an idea that is moving forward.

Journal article J Rheumatol · December 2004 Link to item Cite

Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens.

Journal article Biol Blood Marrow Transplant · August 2004 We report the outcome of 13 patients with advanced malignancies who underwent nonmyeloablative conditioning therapy followed by infusion of partially matched unrelated cord blood cells. The median age of these patients was 49 years, and their median weight ... Full text Link to item Cite

Medical expert systems

Journal article Information Sciences · May 17, 2004 Full text Cite

Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan.

Journal article Medicine (Baltimore) · May 2004 : To determine and directly compare the clinical course of white and Asian patients with paroxysmal nocturnal hemoglobinuria (PNH), data were collected for epidemiologic analysis on 176 patients from Duke University and 209 patients from Japan. White patie ... Full text Link to item Cite

Case based reasoning for medical decision-support in a safety critical environment

Journal article Lecture Notes in Computer Science Including Subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics · December 1, 2003 Case-based reasoning systems applied to safety-critical environments justify specific measures to ensure that the assistance provided is not dangerous to human life. This article presents a case-based reasoning system developed for medical decision-support ... Full text Cite

Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination.

Journal article J Pediatr · October 2003 Rates and severity of pneumococcal infections in children with sickle cell disease were examined before licensure of pneumococcal-conjugated vaccine (PVC). Rates of peak invasive infection rates in 1-year-old children with hemoglobin SS and mortality in th ... Full text Link to item Cite

High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis.

Journal article Blood · October 1, 2003 There were 26 patients enrolled in a pilot study of high-dose immunosuppressive therapy (HDIT) for severe multiple sclerosis (MS). Median baseline expanded disability status scale (EDSS) was 7.0 (range, 5.0-8.0). HDIT consisted of total body irradiation, c ... Full text Link to item Cite

Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases.

Journal article Biol Blood Marrow Transplant · September 2003 High-dose immunosuppressive therapy followed by autologous hematopoietic stem cell transplantation (HSCT) is currently being evaluated for the control of severe autoimmune diseases. The addition of antithymocyte globulin (ATG) to high-dose chemoradiotherap ... Full text Link to item Cite

Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation.

Journal article Bone Marrow Transplant · September 2003 The incidence, etiology, outcome, and risk factors for developing pneumonia late after hematopoietic stem cell transplantation (SCT) were investigated in 1359 patients transplanted in Seattle. A total of 341 patients (25% of the cohort) developed at least ... Full text Link to item Cite

Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia.

Journal article Biol Blood Marrow Transplant · August 2003 We describe previously transfused patients with sickle cell disease (n = 6) and thalassemia (n = 1) who received nonmyeloablative hematopoietic stem cell transplantation (HCT) to induce stable (full or partial) donor engraftment. Patients were 3 to 20 year ... Full text Link to item Cite

Polymyositis as a manifestation of chronic graft-versus-host disease.

Journal article Rheumatology (Oxford) · January 2003 Featured Work OBJECTIVE: Chronic graft-versus-host disease (GVHD) after haematopoietic stem cell transplantation (HSCT) has similarities to some idiopathic autoimmune diseases, including polymyositis. To investigate the relationship between chronic GVHD and idiopathic m ... Full text Link to item Cite

Chronic graft-versus-host disease after allogeneic stem cell transplantation

Journal article Turkish Journal of Cancer · January 1, 2003 Chronic Graft-versus-Host disease (chronic GVHD) is a clinicopathological syndrome which is the major determinant of long-term outcome and quality of life after allogeneic bone marrow or peripheral stem cell transplantation. Chronic GVHD may develop within ... Cite

High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes.

Journal article Blood · September 1, 2002 Featured Work Systemic sclerosis (SSc) is a multisystem disease of presumed autoimmune pathogenesis for which no proven effective treatment exists. High-dose immunosuppressive therapy (HDIT) has been proposed as an investigational treatment for severe autoimmune disease ... Link to item Cite

Bone marrow transplantation for non-malignant disease.

Journal article Int J Hematol · August 2002 Featured Work Full text Link to item Cite

Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias.

Journal article Biol Blood Marrow Transplant · 2002 Featured Work We analyzed effects of successive changes in prevention and treatment of chronic GVHD in 405 patients with aplastic anemia and refractory anemia given HLA-matched hematopoietic stem cell transplantation (HSCT) from 1970-1997. For analysis, patients were di ... Full text Link to item Cite

Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease.

Journal article Transplantation · December 27, 2001 BACKGROUND: In a pilot trial we evaluated the toxicity and efficacy of sirolimus (rapamycin) as second-line therapy for the treatment of acute graft-versus-host disease (GVHD) in 21 patients (1-46 years of age) after allogeneic hematopoietic stem cell tran ... Full text Link to item Cite

Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies.

Journal article Blood · December 15, 2001 Featured Work In the early 1990s, 4 randomized studies compared conditioning regimens before transplantation for leukemia with either cyclophosphamide (CY) and total-body irradiation (TBI), or busulfan (Bu) and CY. This study analyzed the long-term outcomes for 316 pati ... Full text Link to item Cite

Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation.

Journal article Blood · December 15, 2001 Featured Work The duration of immunodeficiency following marrow transplantation is not known. Questionnaires were used to study the infection rates in 72 patients surviving 20 to 30 years after marrow grafting. Furthermore, in 33 of the 72 patients and in 16 donors (sib ... Full text Link to item Cite